
TSHA Stock Forecast & Price Target
TSHA Analyst Ratings
Bulls say
Taysha Gene Therapies Inc. has received regulatory approval for its pivotal TSHA-102 product in the REVEAL Part B clinical trial, effectively mitigating typical delays associated with gene therapies and enabling potential market share growth. The company continues to observe positive trends in patient outcomes across various clinical domains for Rett syndrome, suggesting promising efficacy of TSHA-102, especially at lower doses. Furthermore, ongoing discussions with regulatory agencies aim to define functional gain endpoints, reflecting Taysha's commitment to advancing its innovative gene therapy solutions and enhancing development flexibility with novel applications.
Bears say
Taysha Gene Therapies Inc. faces a challenging regulatory landscape that may lead to delays, impacting investor sentiment negatively, particularly if the development timeline extends longer than anticipated. There is an inherent risk associated with the company's AAV-based gene therapy platform, including potential safety concerns and manufacturing challenges that could further constrain forecasts. Additionally, the unique nature of gene therapies limits the patient pool over time, which may lead to reduced revenue opportunities as each indication becomes saturated.
This aggregate rating is based on analysts' research of Taysha Gene Therapies and is not a guaranteed prediction by Public.com or investment advice.
TSHA Analyst Forecast & Price Prediction
Start investing in TSHA
Order type
Buy in
Order amount
Est. shares
0 shares